Trial Profile
Tolerance Induction Using Autologous Regulatory T Cell Infusion and Zortress (Everolimus) in Renal Transplant Recipients: a Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; T-lymphocyte cell therapy
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2023 Planned End Date changed from 31 Dec 2022 to 30 Jun 2024.
- 13 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2024.